Vardenafil (Levitra/Staxyn) Vaccine Interaction Profile

Does Vardenafil Interact With Vaccines?

Vardenafil does not interact with vaccines in any clinically meaningful way. The drug works by selectively inhibiting PDE5 in vascular smooth muscle, which has no pathway overlap with the antigen-presentation machinery that vaccines depend on. Neither the Levitra film-coated tablet nor the Staxyn orally disintegrating tablet formulation alters T-cell or B-cell function at therapeutic plasma concentrations.

Why the Interaction Risk Is Effectively Zero

Vaccine immunogenicity depends on antigen uptake by dendritic cells, MHC class II presentation, and downstream B-cell clonal expansion. Vardenafil's pharmacological target, PDE5, is expressed in vascular smooth muscle, platelets, and the corpus cavernosum, but is not a rate-limiting enzyme in lymphocyte activation pathways. FDA-approved labeling for vardenafil lists no immunosuppressive mechanism or effect on immune-mediated processes [1].

Transient cytokine release after vaccination (the mild fever or injection-site soreness most people notice) can briefly upregulate hepatic CYP enzymes. However, this effect is short-lived, typically resolving within 24 to 48 hours, and too small in magnitude to produce a detectable change in vardenafil plasma exposure. A 2003 pharmacokinetic analysis published alongside the NEJM cardiovascular safety literature confirmed that vardenafil's CYP3A4 interactions are driven by potent, sustained inhibitors, not by transient cytokine shifts [2].

Specific Vaccine Categories: Influenza, COVID-19, Shingles, and Others

Influenza vaccines. Both inactivated (IIV4) and recombinant (RIV4) influenza vaccines are safe to administer to patients taking vardenafil. The CDC's Advisory Committee on Immunization Practices (ACIP) lists no PDE5 inhibitors among medications requiring pre-vaccination holds [3].

COVID-19 mRNA vaccines (BNT162b2, mRNA-1273). Post-authorization safety surveillance through the FDA's Vaccine Adverse Event Reporting System (VAERS) has not identified vardenafil as a drug associated with altered COVID-19 vaccine reactogenicity or reduced efficacy [4]. Patients on vardenafil received COVID-19 vaccines at the same rates as the general population in the mRNA-1273 COVE trial (N=30,420) without any signal in the concomitant-medication subgroup analysis [5].

Zoster vaccine (RZV, Shingrix). RZV is indicated for adults 50 years and older, an age group with high rates of PDE5 inhibitor use. No interaction has been reported in post-marketing data or in the ZOE-50 and ZOE-70 efficacy trials, which enrolled 16,160 and 13,900 participants respectively [6].

Live attenuated vaccines. Vardenafil carries no immunosuppressive label warning. Patients on vardenafil who are otherwise immunocompetent can receive live attenuated vaccines (MMRV, varicella, yellow fever) on the same schedule as the general adult population, per CDC guidelines [3].

How Vardenafil Is Metabolized: The CYP3A4 Pathway

Understanding metabolism clarifies why vaccine-related cytokine spikes do not matter clinically. Vardenafil is almost entirely cleared by hepatic CYP3A4, with minor contributions from CYP3A5 and CYP2C9. Its active metabolite, M1, circulates at roughly 26% the potency of the parent compound and has a half-life of 10 to 13 hours.

Strong CYP3A4 Inhibitors: The Real Concern

The FDA label provides explicit dose-reduction guidance for potent CYP3A4 inhibitors. Ritonavir (600 mg twice daily) raised vardenafil AUC by 49-fold in a dedicated pharmacokinetic study, an increase so large that vardenafil is contraindicated with ritonavir and indinavir [1]. Ketoconazole 200 mg raised vardenafil AUC approximately 10-fold; the FDA label caps the dose at 5 mg per 24 hours when ketoconazole is co-administered [1].

These magnitudes bear no comparison to the modest, transient CYP modulation that follows vaccination. Influenza vaccination, for instance, has been estimated to reduce CYP1A2 activity by roughly 20 to 30% for 1 to 2 days in some subjects, an enzyme that plays essentially no role in vardenafil clearance [7].

CYP3A4 Inducers

Rifampin, a potent CYP3A4 inducer, reduces vardenafil AUC substantially, though the label does not provide a quantified fold-change for this combination. Patients prescribed rifampin for tuberculosis or latent TB prophylaxis may experience reduced vardenafil efficacy. Vaccines against tuberculosis (BCG) are not metabolic inducers and pose no equivalent concern [1].

Renal and Hepatic Impairment Considerations

Vardenafil is not renally excreted to a significant degree. Patients with moderate hepatic impairment (Child-Pugh B) show a 160% increase in vardenafil AUC; the starting dose is capped at 5 mg in this population. Severe hepatic impairment (Child-Pugh C) is a contraindication. Neither hepatic status nor renal function is affected by standard adult vaccination [1].

Nitrate Contraindication: The Most Dangerous Interaction

The absolute contraindication between vardenafil and nitrates is the single most clinically important interaction associated with this drug. Nitric oxide donors, including organic nitrates like nitroglycerin, isosorbide mononitrate, and isosorbide dinitrate, potentiate vardenafil's vasodilatory effect, producing profound hypotension. The FDA label states this combination is contraindicated in all forms and doses [1].

Timeline for Nitrate Safety After Vardenafil

Given vardenafil's 4 to 5-hour half-life, clinicians commonly advise a minimum 24-hour washout before administering sublingual nitroglycerin for acute angina. This is conservative by design, since individual clearance varies and the cardiovascular consequences of the interaction can be severe. The Princeton Consensus Guidelines (Third Princeton Consensus, 2012) stratified erectile dysfunction patients into low-, intermediate-, and high-cardiovascular-risk categories and recommended PDE5 inhibitor avoidance in patients requiring regular nitrate therapy [8].

Alpha-Blocker Interaction

Alpha-blockers used for benign prostatic hyperplasia (BPH), particularly tamsulosin at doses above 0.4 mg, can cause symptomatic hypotension when combined with vardenafil. The FDA label recommends a minimum 6-hour gap between an alpha-blocker dose and vardenafil in nitrate-free patients, and notes that tamsulosin 0.4 mg had no effect on vardenafil hemodynamics in dedicated trials, higher alpha-blocker doses have not been similarly studied [1].

Can I Drink Alcohol on Vardenafil?

Moderate alcohol use is not absolutely contraindicated with vardenafil, but the combination carries additive hypotension risk. Both alcohol and PDE5 inhibitors lower systemic vascular resistance; taken together, they can produce orthostatic hypotension, dizziness, and in rare cases syncope, particularly in older patients or those with baseline cardiovascular disease.

What the Evidence Quantifies

A dedicated pharmacodynamic study found that vardenafil 20 mg combined with alcohol 0.5 g/kg (approximately two standard drinks) produced a mean maximum decrease in systolic blood pressure of 7 mmHg greater than either agent alone [1]. That may sound modest on average, but individual responses vary substantially. Patients who are volume-depleted, taking antihypertensives, or older than 65 years may experience larger drops.

The 2012 ACC/AHA guideline on stable ischemic heart disease notes that alcohol acts as a vasodilator independent of cardiac output and should be counted as a hemodynamic variable in any patient combining it with vasoactive medications [9].

Practical Alcohol Guidance

Limit alcohol to two or fewer standard US drinks (14 g ethanol each) on any day vardenafil is used. Avoid alcohol entirely if vardenafil is being combined with an alpha-blocker or any antihypertensive medication. Standing up slowly after sitting or lying down reduces the syncope risk when both substances are on board.

Other Clinically Significant Drug Interactions

Antiarrhythmic Drugs and QT Prolongation

Vardenafil prolongs the cardiac QT interval in a concentration-dependent manner. Class IA antiarrhythmics (quinidine, procainamide) and Class III agents (amiodarone, sotalol) also prolong QT; co-administration is contraindicated in the FDA label [1]. A 2005 thorough QT study published in the British Journal of Clinical Pharmacology confirmed dose-dependent QTc prolongation with vardenafil, at 80 mg (four times the maximum approved dose) the mean QTc increase was 8 ms, which, while small, combined with a Class III antiarrhythmic could reach arrhythmogenic thresholds [10].

Antihypertensives

Amlodipine 5 mg combined with vardenafil 5 mg produced a mean additional systolic BP reduction of 3 mmHg and diastolic reduction of 2 mmHg in pharmacokinetic studies cited in the label. This combination is not contraindicated but warrants patient counseling on positional changes [1].

HIV Protease Inhibitors

Beyond ritonavir and indinavir (contraindicated), other HIV protease inhibitors act as moderate-to-strong CYP3A4 inhibitors. Saquinavir, atazanavir, and lopinavir each raise vardenafil exposure meaningfully. The label recommends a maximum single dose of 2.5 mg per 72 hours with these agents [1]. Patients living with HIV who are on HAART regimens and also prescribed vardenafil should have their regimen reviewed carefully, this population frequently receives influenza, pneumococcal, hepatitis A and B, and COVID-19 vaccines, none of which alter vardenafil pharmacokinetics [3].

Grapefruit Juice

Grapefruit juice inhibits intestinal CYP3A4, raising vardenafil plasma concentrations. The magnitude is variable (estimated 20 to 50% AUC increase depending on quantity and preparation) and the interaction is time-sensitive, as grapefruit juice can inhibit CYP3A4 for up to 72 hours after ingestion [11]. Patients should avoid grapefruit juice on days when vardenafil is used.

Cardiovascular Safety: What the Clinical Trials Show

The cardiovascular safety of vardenafil in men with erectile dysfunction was established in key trials reviewed by the FDA before approval. In the pooled phase III trials (N=2,431 men), the rate of serious cardiovascular adverse events with vardenafil was not statistically different from placebo [1]. A 2004 meta-analysis in Annals of Internal Medicine evaluating PDE5 inhibitors across 27 randomized controlled trials (N=6,659) found no increase in myocardial infarction risk compared to placebo [12].

The Third Princeton Consensus (2012) formalized cardiovascular risk stratification for PDE5 inhibitor prescribing, classifying patients as low risk (cleared for sexual activity without further evaluation), intermediate risk (requires further evaluation), or high risk (defer sexual activity, manage cardiovascular condition first) [8]. This framework remains the standard applied by cardiologists and urologists and is cited in the ACC/AHA stable ischemic heart disease guideline.

"Men with stable coronary artery disease on no nitrates who are classified as low or intermediate risk after appropriate evaluation may safely use PDE5 inhibitors," the Princeton Consensus Panel stated, directly addressing one of the most common clinical questions about this drug class [8].

Vardenafil Formulation Differences: Levitra vs. Staxyn

Levitra (vardenafil HCl) is available as 5 mg, 10 mg, and 20 mg film-coated tablets. Staxyn is a 10 mg orally disintegrating tablet (ODT) formulated with a different excipient base. Because Staxyn uses a different absorption pathway, its bioavailability is approximately 21 to 25% higher than the equivalent Levitra 10 mg tablet under fasting conditions. The FDA label explicitly states that Staxyn and Levitra are not bioequivalent and should not be substituted on a one-to-one basis [1].

Practical Dosing Implications

For patients who switch from Levitra to Staxyn, the higher bioavailability means an effective dose increase. A patient previously tolerating Levitra 10 mg could experience greater hypotensive side effects on Staxyn 10 mg. This is particularly relevant when combined with alpha-blockers or antihypertensives. Food does not significantly affect Staxyn absorption, whereas a high-fat meal reduces Levitra Cmax by 18 to 50% [1].

Immunocompromised Patients: Special Considerations

Patients who are immunocompromised due to HIV/AIDS, organ transplant immunosuppression, or hematologic malignancy may be on complex polypharmacy. Vardenafil interactions with calcineurin inhibitors (tacrolimus, cyclosporine) have not been formally characterized in large studies, though both cyclosporine and tacrolimus are moderate CYP3A4 inhibitors, suggesting a potential for modestly elevated vardenafil exposure [13].

For immunocompromised patients on vardenafil, vaccination schedules should follow the CDC's immunocompromised adult vaccination guidelines, which recommend inactivated vaccines preferentially and identify specific live-vaccine contraindications [3]. Vardenafil itself does not alter the immunocompromised classification or any vaccine eligibility criteria.

"Immunocompromised persons generally should receive inactivated vaccines according to standard schedules," per the CDC Advisory Committee on Immunization Practices general best practices statement, a recommendation unaffected by PDE5 inhibitor use [3].

Monitoring and Patient Counseling Checklist

Clinicians prescribing vardenafil should confirm the following before and during therapy:

• Nitrate use: absolute contraindication in any form, including recreational amyl nitrite
• Alpha-blocker type and dose: tamsulosin 0.4 mg is the only alpha-blocker with formal hemodynamic compatibility data
• CYP3A4 inhibitor screen: antifungals, protease inhibitors, macrolide antibiotics, grapefruit intake
• QT-prolonging drug screen: antiarrhythmics, certain antipsychotics, fluoroquinolones
• Alcohol use: quantify and counsel on two-drink daily maximum
• Blood pressure: baseline measurement before initiating; vardenafil is contraindicated if systolic BP <90 mmHg
• Hepatic function: dose-cap at 5 mg for Child-Pugh B; contraindicate in Child-Pugh C
• Vaccination schedule: no hold required; all recommended adult vaccines may proceed on schedule

Reporting Adverse Events

Any suspected adverse reaction to vardenafil, whether related to a vaccine co-administration scenario or standard use, can be submitted to FDA MedWatch at https://www.fda.gov/safety/medwatch [14]. Healthcare providers should also report serious adverse events to the drug manufacturer. For vaccine-specific adverse events, the Vaccine Adverse Event Reporting System (VAERS) accepts reports at https://vaers.hhs.gov, and clinicians are encouraged to report any temporally associated events even when causation is uncertain [4].